Reata reports Phase Ib data for omaveloxolone in melanoma

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported interim data from 30 evaluable patients with unresectable or metastatic melanoma in the Phase Ib portion of the Phase Ib/II REVEAL trial showing that omaveloxolone (oral RTA 408) plus Yervoy ipilimumab or Opdivo nivolumab led to an overall response rate (ORR) of 27%, including two complete responses and six partial responses. Data were presented at the European Society for Medical Oncology Immuno Oncology meeting in Geneva.

The open-label, dose-escalation, dose-expansion, U.S. trial plans to enroll about 102 patients...